Manufacturing

The medical landscape is currently grappling with a profound paradox as the most promising frontier in immunology faces an unprecedented crisis of confidence. The biopharmaceutical sector must now determine if the high levels of toxicity tolerated in oncology are an acceptable trade-off for

Piramal Pharma is currently evaluating 38% of its critical suppliers against strict environmental, social, and governance criteria to ensure sustainability throughout the entire value chain. This initiative represents a fundamental shift in how the pharmaceutical industry approaches procurement,

While cloud-based applications remained secure, the compromise of on-premises systems halted the ability of a major manufacturer to fulfill essential medical hardware orders. This incident sent immediate shockwaves through the global healthcare sector, highlighting the precarious dependency on

Gland Pharma's Visakhapatnam Special Economic Zone Sterile Oncology Facility recently achieved a No Action Indicated status following a USFDA inspection with zero Form 483 observations. This significant regulatory outcome underscores the firm’s commitment to maintaining the highest quality

The U.S. Food and Drug Administration has historically maintained a tight grip on international regulatory priorities to prevent them from drifting away from its own preferences. This level of control is necessary because the global medical device industry currently operates within a fragmented

Industrial biomanufacturing efficiency is often compromised because the behavior of a cell population can change significantly from the early phase to high-density growth. This phenomenon creates a fundamental disconnect between the highly controlled blueprints of synthetic biology and the messy,